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http://dx.doi.org/10DNA methylation is a well-studied epigenetic modification essential for efficient cellular differ-
entiation. Aberrant DNA methylation patterns are a characteristic feature of cancer,
including myeloid malignancies such as acute myeloid leukemia. Recurrent mutations in
DNA-modifying enzymes were identified in acute myeloid leukemia and linked to distinct
DNA methylation signatures. In addition, discovery of Tet enzymes provided new mechanisms
for the reversal of DNA methylation. Advances in base-resolution profiling of DNA methyl-
ation have enabled a more comprehensive understanding of the methylome landscape in
the genome. This review will summarize and discuss the key questions in the function of
DNA methylation in the hematopoietic system, including where and how DNA methylation
regulates diverse biological processes in the genome as elucidated by recent studies.  2014
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Open access under CC BY-NC-ND license.The presence of 5-methylcytosine (5mC) in nucleic acid was
first discovered among the hydrolysis products of tubercu-
linic acid in 1950 [1]. It has long been studied as a part of
the genetic code, with limited understanding of its impor-
tance inmammalian cells until 1975,whenDNAmethylation
reached a milestone with the identification of roles in tran-
scriptional regulation of development and X chromosome
inactivation [2,3]. The discovery of CpG islands suggested
candidate regions in the genome for methylation study [4],
and, since then, intensive studies have expanded our under-
standing of the diverse effects of DNAmethylation in various
organisms and different tissue types, particularly in the
context of CpG islands. These studies have led to the elucida-
tion of the molecular pathways required for establishing and
maintaining DNA methylation, of cell-type-specific varia-
tion in methylation patterns, and of the involvement of
methylation in multiple cellular processes such as transcrip-
tion regulation, cellular differentiation, tumorigenesis, X
chromosome-inactivation, and imprinting [5–10]. Under-
standing the function of DNAmethylation requires consider-
ation of the distribution of methylation across the genome.
Genome-wide studies of DNA methylation have begun
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.1016/j.exphem.2014.04.008only capture a small fraction of the genome [12–14]. Howev-
er, followed by the advent of high-throughput sequencing
technology, single-base resolution, genome-wide DNA
methylation data are now available. In this review, we will
discuss recent discoveries about genome-wide distribution
of 5-methylcytosine, as well as the role of cytosine-
modifying enzymes and their somatic mutations in hemato-
poietic malignancies, to achieve a better understanding of
the functional roles of DNA methylation and therapeutic
applications.DNA methylation and demethylation
DNA methylation commonly involves modification of cyto-
sines. The mammalian DNA methyltransferase (DNMT)
family is made up of five members: DNMT1, DNMT2,
DNMT3A, DNMT3B, and DNMT3L. The maintenance
methyltransferase, DNMT1, is responsible for maintaining
the methylation pattern during replication and adds methyl-
ation to DNA when one strand is already methylated. De
novo methyltransferases DNMT3A and DNMT3B create
hemimethylated CpG dinucleotides to establish new pat-
terns of methylation (Fig. 1A). Their activity can be modu-
lated by the catalytically inactive family member
DNMT3L; however, DNMT3L is primarily restricted to
early embryogenesis, so it does not play a major role
[8,15,16]. In mammalian genomes, 5mC exists mostly in
the CpG dinucleotide context, and about 70%–80% of
CpGs are methylated. Although the DNA methylationPublished by Elsevier Inc. Open access under CC BY-NC-ND license.
Figure 1. The DNA methylation and demethylation pathway. Overview of the DNA methylation and demethylation process. DNMT1 is responsible for
maintenance methylation. (A) DNMT1 adds methylation to hemimethylated DNA when one strand is already methylated. DNMT3a and DNMT3b are
responsible for de novo DNA methylation. They create hemimethylated CpG dinucleotides to establish new patterns of methylation. (B) Passive demethy-
lation occurs through loss of DNMT1/3 (via loss of gene expression, gene mutation, or possibly via other mechanisms that inhibit protein function). Active
demethylation is mediated by Tet-family proteins. 5mC can be hydroxylated to 5hmC by Tet proteins. 5hmC is not recognized by the maintenance meth-
yltransferase (DNMT1), so the methylation is lost during DNA replication. In addition, 5hmC can be further oxidized to 5fCs and 5caCs and may be removed
by base-excision repair in an alternate mode of active demethylation (in addition to loss of the 5hmC by cell division).
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methylation can be removed passively by blocking methyl-
ation of newly synthesized DNA during DNA replication.
Global DNA demethylation is important for resetting
pluripotent states in early embryos and for erasing
parental-origin-specific imprints in developing germ cells
[17]. Recent compelling genetic and biochemical data
indicate that genomic methylation patterns can be changed
by active demethylation (Fig. 1B). The discovery of the
Tet family of enzymes, which can modify 5mC through
oxidation, was another milestone in advancing our
understanding of DNA demethylation mechanisms, intro-
ducing 5-hydroxymethylcytosine (5hmC) as a key interme-
diate, as well as the further oxidized intermediates
5-formylcytosine (5fC) and 5-carboxycytosine (5caC), in
active demethylation pathways [18–20].
Who is the main player in hematopoiesis?
Hematopoietic stem cells are the best characterized somatic
stem cells, and the differentiation hierarchy that emanates
from them is well characterized [21]. As epigenetic changes
facilitate lineage-specific differentiation, hematopoiesis
provides a well-defined model to study dynamic DNA
methylation changes during cell-fate decisions. Moreover,
abnormal DNA methylation patterns are characteristic fea-
tures of hematologic malignancies, further compelling us tounderstand the role of DNA methylation changes during
normal and aberrant hematopoietic development.
The de novo methyltransferase DNMT3a has recently
been shown to be essential for hematopoietic stem cell dif-
ferentiation [22], and other groups identified somatic muta-
tion of DNMT3A in w30% of normal karyotype acute
myeloid leukemia (AML) [23,24], pointing to the funda-
mental role of 5mC in hematopoietic differentiation and
disease. The most common mutation of DNMT3A in
AML is R882H, which is within the catalytic domain.
This mutation functions as a dominant-negative inhibitor
of de novo DNA methylation in an embryonic stem (ES)
cell model system, as well as in human AML cells
[25,26]. Active DNMT3B and DNMT3L are expressed in
murine ES cells and contribute to methylation activities.
However, in AML cells, DNMT3L is not expressed, and
an inactive splice isoform is the dominant form of
DNMT3B, suggesting that the de novo DNA methylation
potential in hematopoiesis is largely provided by DNMT3A
[26].
The methylcytosine oxidase is essential for hematopoiet-
ic stem cell homeostasis. Tet methylcytosine dioxygenase 2
(TET2) inactivation in the mouse resulted in multiple he-
matopoietic abnormalities, and, ultimately, in myeloprolif-
eration and a chronic myelomonocytic leukemia
(CMML)-like disease [27–29]. Moreover, TET2 mutations
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ted myeloid differentiation, including AML, myelodysplas-
tic syndrome (MDS), myeloproliferative neoplasms (MPN),
and CMML [30–34]. In addition, the isocitrate dehydroge-
nase (IDH) family of enzymes catalyzes the oxidative
decarboxylation of isocitrate to alpha-ketoglutarate
(aKG). Mutations in IDH1/2 have recently been identified
that lead to the abnormal accumulation of 2-
hydroyglutarate (2HG), which inhibits aKG-dependent en-
zymes, including Tet-mediated DNA demethylation. Thus,
mutant IDH mimics TET2 mutation and results in increased
levels of 5mC and decreased levels of 5hmC. Mutation of
IDH1/2 has been found in gliomas, AMLs, and MPNs
[29,35,36], and direct measurement of 2HG in IDH1/2-
mutant AML can detect one-hundredfold-increased 2HG
levels in some patients, consistent with a gain of function
of the mutant enzyme. The incidence of these newly found
mutations related to DNA methylation are considerable in
hematologic malignancies, resulting in alterations in DNA
methylation and aberrant gene expressions patterns
(Table 1).Genomic distribution of DNA methylation
The human and mouse genomes have approximately 28
million and 22 million CpGs, respectively. Around 7% of
CpGs reside within CpG islands (CGIs) [37], and the ma-
jority of CpG sites exist outside of CGIs. In most cell types,
CpGs have stable methylation patterns, and onlyw20% of
CpGs are dynamic [38]. Depending on the genomic loca-
tion, DNA methylation may have different biological func-
tions. It is therefore important to map the DNA methylation
changes in different physiologic states and examine the in-
fluence on expression of nearby genes. Promoter CGIs have
a low methylation ratio, which is often increased in cancer
cells, contributing to gene silencing. Nonpromoter CGIs
show variable methylation ratios, and the methylation
changes in these regions are often tissue-specific. Gene
bodies are highly methylated, and the methylation is asso-
ciated with active expression and may have an impact onTable 1. Mutations in DNA modifiers in hematologic malignancies
Gene Malignancy Mutation % References
DNMT3A AML 12%–22% [22,23,29,102]
MDS 8%
MPN 7%–15%
MDS/MPN 4%
TET2 AML 12%–34% [31,103–106]
MDS 20%–25%
MPN 4%–14%
CMML 50%
IDH1/2 AML 15%–33% [35,107–110]
MDS 3.50%
T-ALL 2.5%–5%
T-cell lymphoma 5%–10%
T-ALL 5 T-cell acute lymphoblastic leukemia.splicing. Repeat elements are frequently methylated, and
loss of methylation in these regions has been postulated
to be associated with chromosome instability. Thus, sup-
pression of the expression of transposable elements by
methylation may be important for genome stability.
Genome-wide high resolution methylation studies have
enabled us to observe more detailed methylome architec-
tures such as CGI shores, methylation canyons, and large
hypomethylated regions. Here, we summarize more details
about each of these regions (Fig. 2) and show, for murine
hematopoietic stem cells (HSCs), how the DNA methyl-
ation ratios vary for given genomic features (Table 2).Promoter CGIs
Approximately 70% of the genes in the genome contain
short, CpG-rich regions known as CGIs, whereas the
remainder of the genome is depleted for CpGs [39]. Most
studies have focused on 5mCs in a CpG context, and
much of the work on DNA methylation has focused on
CGIs at promoter regions at the single-gene level. Most
promoter CGIs are largely unmethylated in normal tissues,
regardless of their differentiation state [40]. When genes
with CGIs at the promoter are unmethylated, their
promoters are usually characterized by nucleosome-free re-
gions at the transcriptional start site. These nucleosome-
free regions are often marked with Histone H3 lysine 4
tri-methylation (H3K4me3) [41], and the levels of tran-
scription are controlled by associated transcription factors.
Transcription at some promoters is repressed by various
mechanisms, such the polycomb complex and Histone H3
lysine 27 tri-methylation (H3K27me3) [42]. Methylation
in promoter-CGI regions in normal cells is usually
restricted to genes at which there is long-term silencing,
such as the inactive X chromosome and imprinted genes,
as well as genes that are exclusively expressed in germ cells
but not in somatic cells [43]. However, in hematologic ma-
lignancies, many promoter CGIs become aberrantly hyper-
methylated. In particular, hypermethylation of cell-cycle
regulators, apoptosis, and DNA repair genes are thought
to contribute to reduced expression and the promotion of
transformation [44,45].Figure 2. Graphical representation of the dynamic methylome landscapes
in various genomic regions. DNA methylation level variation across each
feature is represented using colors from level 0 (blue) to 1.0 (red).
Enhancer regions, CGI shores, and canyon edges represent the most differ-
entially methylated features [38,60].
Table 2. Mouse hematopoietic stem cell methylation ratio in various
genomic regions
Genomic regions Methylation ratio
All 83.52%
Canyons 4.33%
CGI 7.71%
CGI shore 48.02%
Gene 82.68%
Intron 84.45%
Exon 72.40%
Promoter 23.78%
5’UTR 68.61%
3’UTR 83.07%
LINE 88.53%
LTR 89.79%
SINE 90.03%
CTCF binding regions 41.04%
Bivalent domains 4.70%
H3K4me3 binding regions 9.35%
H3K27me3 binding regions 43.04%
H3K36me3 binding regions 94.03%
Gata2 binding regions 47.26%
PU.1 binding regions 17.48%
Gata2 5 GATA binding protein 2; H3K27me35 Histone H3 lysine 27 tri-
methylation; H3K36me3 5 Histone H3 lysine 36 tri-methylation;
H3K4me3 5 Histone H3 lysine 4 tri-methylation; LINE 5 long inter-
spersed element; LTR 5 long terminal repeat; SINE 5 short interspersed
element; UTR 5 untranslated region.
All data from Sun et al. [54].
612 M. Jeong and M.A. Goodell/ Experimental Hematology 2014;42:609–617CGI shores
In recent years, genome-wide approaches have facilitated
the analysis of regions outside of promoters and CGIs
and are thus expanding our understanding of DNA methyl-
ation in different cell types (including stem and differenti-
ated cells). Comprehensive high-throughput arrays for
relative methylation assays revealed that tissue- and
cancer-specific differentially methylated regions occur
more frequently within CGI shores and regions of relatively
low CpG density that flank traditional CGIs (up to 2 kb in
distance) than within CGIs themselves, suggesting the
involvement of CGI-shore methylation in tissue differenti-
ation, epigenetic reprogramming, and cancer [46,47]. Meth-
ylome studies in hematopoietic lineages showed differential
methylation regions in numerous genes known to play a
role in lymphoid- or myeloid-fate specification, and differ-
ential methylation occurs more frequently in CGI shores
than CGIs during the differentiation process [48].Enhancers
Little is known about DNAmethylation in intergenic regions.
These regions contain functionally important elements such
as enhancers. Recently, low methylation regions and
unmethylated regions have been suggested to function as en-
hancers [49]. Transcriptional enhancers support tissue-
specific expression profiles through physical interactionswith gene promoters. Unmethylated promoters are permis-
sive of, but not necessary for, transcription initiation.
Enhancer methylation associates with cell-specific transcrip-
tion levels, even when the promoter is constantly unmethy-
lated. These sites bind chromatin-modulating factors,
interact with distal promoters through DNA loops, and
demonstrate a unique pattern of DNA methylation in
different cell types. Global mapping of DNA methylation
at different stages of hematopoiesis shows that differential
methylated regions are enriched for transcription factor bind-
ing sites (TFBSs), and specific hypomethylation at myeloid
TFBSs is observed in lymphoid progenitors [50]. Bock
et al. also observed that binding sites of key myeloid-
specific factors (GATA binding protein 2, T-cell acute lym-
phocytic leukemia 1, and LIM domain only 2) became
robustly methylated during lymphoid differentiation [51].
Similarly, Sun et al. found that TFBSs of key HSC-
associated transcription factors (e.g., stem cell leukemia
[Scl]/Tal1) became hypomethylated in aging HSCs, while
those of differentiation-associated transcription factors
(e.g., PU.1) were more likely to become hypermethylated,
likely contributing to enhancing self-renewal and inhibiting
differentiation with age [52–54].Large hypomethylated regions and methylation canyons
Genome-wide approaches have identified additional large
regions with important alterations in methylation in cancer
and cell-fate decisions. Not only can epigenetic deregula-
tion occur at single genes, it can also encompass large chro-
mosomal domains during differentiation and tumorigenesis.
Hansen et al. found large hypomethylated blocks to be en-
riched for genes with hypervariable expression in colon
cancer, which could drive tumor cell heterogeneity [55].
Large hypo-methylated regions have been identified by
comparing differentiated fibroblasts to human ES cells.
These have been termed partially methylated domains
[56]. The loss of methylation in these regions is accompa-
nied by acquisition of repressive histone marks, and genes
in these domains are downregulated [55,57]. Long-range
epigenetic activation domains are large regions that typi-
cally span 1Mb and harbor key oncogenes and cancer
biomarker genes, while long-range epigenetic silencing do-
mains harbor key tumor suppressors and miRNAs and were
discovered in cancer cells [58,59].
Jeong et al. identified exceptionally large regions with
very low levels of methylation (DNA methylation canyons)
in hematopoietic stem cells, which showed novel epige-
nomic features [60]. They are conserved across species
and cell types, and dynamic DNA methylation changes
occur at the edge of canyons in the absence of DNMT3a.
Similar features have been reported in ES cells and termed
DNA methylation valleys [61]. Altered large domain meth-
ylome architectures are associated with changes in tran-
scriptional output and altered genomic stability that
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progression.Gene body methylation
Most gene bodies are CpG-poor and extensively methyl-
ated. Although most CGIs are located in promoter regions,
CGIs also exist within the gene bodies. Gene body methyl-
ation is not associated with gene repression; instead, posi-
tive correlations between active transcription and gene
body methylation have been reported [62]. DNA methyl-
ation in human cells has identified hypermethylation in
the gene bodies of actively transcribed genes [14,56]. Study
of chronic lymphocytic leukemia patients revealed that sites
of DNA hypomethylation in the gene body are mostly
enhancer sites; the investigation also recognized a DNA
methylation signature that distinguishes new clinicobiolog-
ical subtypes of chronic lymphocytic leukemia [63]. Gene
body methylation may also regulate tissue-specific expres-
sion from alternative promoters [64]. Distinctive epigenetic
patterns in the gene body, including DNA methylation and
nucleosome positioning, have been identified around exons
and exon–intron borders, suggesting that chromatin struc-
ture is also important to exon selection [65]. DNA methyl-
ation in gene bodies may facilitate exon exclusion via
recruitment of the multifunctional CpG binding proteins
[66]. DNA methylation inhibits CCCTC-binding factor
(CTCF) binding to exons, and this prevents CTCF-
mediated RNA polymerase II pausing and spliceosome as-
sembly [67]. Thus, DNA methylation in gene bodies has
functions distinct from that of promoter methylation. How
gene-body methylation levels are regulated and the under-
lying mechanisms through which methylation exerts an in-
fluence on gene expression are just beginning to be
elucidated.Repeats and ribosomal DNA
Repetitive elements are DNA sequences that are present in
multiple copies in the genomes in which they reside.
Methylation in repeat regions, such as centromeres, is
important for chromosomal stability during mitosis [68]
and is also likely to suppress the expression of transposable
elements and thus to have a role in genome stability. Recent
data have also identified a role for tissue-specific retro
element hypomethylation in association with enhancer ac-
tivity [61]. Whole genome bisulfate sequencing data from
DNMT3B-mutant immunodeficiency, centromeric insta-
bility, and facial anomalies patients showed profound
changes in inactive heterochromatic regions, satellite re-
peats, and transposons. Such changes cause aberrant
expression of immune genes and hypomethylation of peri-
centromeric regions accompanied by chromosomal insta-
bility. Interestingly, however, transcriptionally active loci
and ribosomal RNA (rRNA) repeats escaped global hypo-
methylation [69]. The genes encoding rRNA are the mostabundant genes in the genome. They reside in tandem re-
petitive clusters, in some cases totaling hundreds of copies.
Owing to their repetitive structure and highly active tran-
scription, the rRNA gene repeats are some of the most frag-
ile sites in the chromosome. In CD34þ hematopoietic
progenitor cells from MDS patients, reduced rRNA expres-
sion and increased rDNA promoter methylation were
observed compared with controls. Treatment of myeloid
cell lines with 5-aza-2’-deoxycytidine resulted in a
significant decrease in the methylation of the rDNA pro-
moter and an increase in rRNA levels [70].The role of 5-hydroxymethylcytosine
After the discovery of different levels of 5hmC in various
mouse and human cells, several studies suggested that there
is a fine balance between 5mC and 5hmC that is critical for
maintaining the normal state of cells [18,20,71,72].
Because 5hmC is not recognized by DNMT1, as the
DNA is replicated, the methylation at that site is lost,
thus offering a passive mechanism for DNA demethylation
[73]. However, active DNA demethylation in the presence
of 5hmC has also been proposed to occur via the base exci-
sion repair pathway [74]. Finally, 5hmC may have other
specific functional roles in gene expression aside from
facilitating removal of DNA methylation. To understand
these possible roles, the location of 5hmC must first be
mapped at the base-resolution level.
Detecting genome-wide 5hmC distribution is chal-
lenging because of its low abundance. Through the use
of available technologies, which include cytosine-5-
methylenesulfonate sequencing [75], hydroxymethyl DNA
immunoprecipitation sequencing [76], oxidative bisulfate
sequencing [77], and Tet-assisted bisulfite sequencing
[78], some conserved features of the 5hmC landscape
have emerged. In immune cell populations, 5hmC is present
at 1% of the total level of 5mC [34], compared with 5%–
10% of the level of 5mC in ES cells and 40% of 5mC in
neuronal cells [18,20,72]. Genome-wide mapping of Tet1
and 5hmC in ES cell genomic DNA indicates that Tet1
and 5hmC are enriched at transcription start sites with spe-
cific histone modifications known to be associated with
inactive genes. This suggests that 5hmC may contribute
to the poised chromatin signatures at developmentally regu-
lated genes [79,80]. Other studies yielded opposite results,
including a correlation between 5hmC and histone modifi-
cations in enhancer regions of human ES cells and 5hmC in
promoters and exon regions with increased levels of tran-
scription [81–83]. It is possible that an independent mech-
anism can directly cause hydroxymethylation of the
cytosines in a site-specific manner [84]. Tissue-specific
differentially hydroxymethylated regions are located in
the intragenic regions of the genome with intermediate
guanine-cytosine content [83]. Studies of 5hmC in human
CD34þ and in several erythroid developmental stages
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the erythroid lineages [85]. In addition, gain of 5hmC at the
genomic loci of erythroid-specific transcription factor bind-
ing sites and loss of 5hmC at transcriptionally repressed
genes such as CD34 were shown [85]. Finally, rapid
DNA demethylation occurs during erythropoiesis [86],
and this is likely to occur via a Tet-mediated mechanism.
These findings suggests that 5hmC influences cell-specific
transcriptional programs during differentiation, thereby
facilitating gene expression. Overall, the discovery of the
importance of the Tet family of proteins has transformed
our views of DNA demethylation and underscored the
importance of dynamic DNA methylation in cell-fate deci-
sions and gene regulation. We are at the very start of under-
standing the detailed mechanisms through which these
proteins act in hematopoiesis.The mechanism of DNA methyltransferase
inhibitors in malignancies
The two approved DNA demethylating drugs, decitabine
(DAC) and its analogue azacitidine, are irreversible inhibi-
tors of the DNA methyltransferase enzymes DNMT1 and
DNMT3 [87,88]. These drugs become incorporated into
DNA, trap DNMTs, and target these enzymes for degrada-
tion. They are potent drugs for MDS, leukemias, and mul-
tiple types of solid tumors [89–91], and the clinical data
suggest responses in about half of patients [92,93]. Despite
the clinical efficacy of DNA methyltransferase inhibitors
(DNMTIs), there is still a lack of understanding of the
mechanism through which they function. Earlier studies re-
ported that the activity of DNMTIs in cancers results from
their ability to induce a DNA-damage response and
apoptosis [94–96]. More recent studies indicated that treat-
ment of cancer cells with clinically relevant low doses of
DAC and azacitidine can selectively hypomethylate aber-
rantly methylated CpGs and reactivate repressed genes
without inducing immediate cytotoxic effects such as
DNA damage, apoptosis, and cell-cycle arrest [97]. A num-
ber of studies have shown that DAC maintains normal HSC
self-renewal but induces terminal differentiation in leuke-
mia cells [87,98–100]. However, the mechanisms of sensi-
tivity and resistance to DNMTIs are still open with
questions. One of the important goals of genome-wide
profiling of DNA methylation is to identify differences be-
tween malignant cells and normal cells that can be ex-
ploited for therapy.Conclusions and perspectives
Recent advances in DNA methylation mapping have altered
our view of the most dynamic sites of de novo methylation
and demethylation, revealing that these changes occur more
frequently in distal regions such as CGI shores, canyon
edges, and enhancers with low CpG densities, rather than
CGIs with high CpG density. In addition, 5hmC and Tetproteins are detected at these regions [60,82,101]. How
CpGs in these genomic regions are selectively targeted by
DNMTs and Tets, as well as the mechanisms through which
they impact gene expression and cancer, are critical remain-
ing questions.
Recent discoveries of the importance to normal and ma-
lignant hematopoiesis of the proteins involved in DNA
methylation and demethylation have transformed our
outlook on gene regulation during hematopoiesis. Fortu-
itously, the discoveries of the importance of proteins such
as TET2 and DNMT3A have come at a time when our
capacity to identify DNA methylation modifications at
base-pair resolution has been enormously facilitated by a
dramatic drop in the cost of high-throughput sequencing.
Thus, we are presented with a new opportunity to study
DNA methylation changes in normal and malignant hema-
topoiesis by careful mapping. Although it is possible that
the proteins involved in DNA methylation also have alter-
native functions perturbed by mutation, it is essential to
map the DNA methylation changes and correlate these to
changes in gene expression and cellular function. Through
this focused approach, we will eventually shed light on how
these mutations exert their powerful influence on cellular
physiology.
Clinical studies of DNMTIs have demonstrated that tar-
geting DNA methylation is selective, making it an efficient
strategy for targeting malignant cells but not for normal
HSCs. Despite these findings, much still remains to be un-
derstood, including the distribution of oxidized 5mC bases
(5hmC/5fC/5caC) in the genome and their role during
cellular processes, determination of the exact genes or
loci that are important in their pathophysiology, and identi-
fication of the signature of DNA methylation that is predic-
tive of therapeutic response. Ongoing genome-wide studies
with advanced bioinfomatic analysis, along with rapid and
cost-effective sequencing techniques, will allow us to
address many remaining questions.Acknowledgments
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